EC Domain for Exposure as Collected in FDA Study Data
FDA’s June 2026 guide defines the role of the EC domain for protocol-specified study-treatment administrations captured as collected.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
FDA’s June 2026 guide describes the EC (Exposure as Collected) domain as providing protocol-specified study-treatment administrations as collected and as a way to address challenges in representing a subject’s study-medication exposure.
Key details
Core IssueFDA’s June 2026 guide defines the role of the EC domain for protocol-specified study-treatment administrations captured as collected.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This is current FDA technical-conformance guidance for electronic study-data submissions; recheck the current FDA guide, supported standards, Data Standards Catalog, and eCTD specifications before relying on version-sensitive requirements.
Further guidance
Content
Use the EC domain for protocol-specified study-treatment administration information as collected, within the supported SDTM submission context described by FDA.
Purpose
Preserve as-collected treatment-administration information in the domain FDA identifies for that purpose.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
FDA’s June 2026 guide describes the DD (Death Details) domain for supplemental information collected when a death occurs and expects consistency with relevant AE-domain death variables.
FDA’s June 2026 conformance guide says screen failures, when provided, should be represented as a DM record with specified planned/actual arm fields left blank.
FDA’s June 2026 guide gives DS-domain handling for multiple disposition events, including use of EPOCH or DSSCAT and a specific final-record convention for death.
FDA’s June 2026 guide explicitly calls for the DV domain in submissions containing protocol-deviation data and identifies review-oriented variables beyond CDISC-required fields.
FDA’s June 2026 guide gives a direct placement rule for viral-load results in standardized clinical study data: place them in the MB (Microbiology) domain.
FDA’s June 2026 guide states an Agency preference for submitting scheduled and unscheduled clinical subject visits together in one dataset structured as the current SDTM SV domain.
FDA’s June 2026 guide says the AE domain should include all adverse events unless an indication-specific technical specification says otherwise and asks for the criterion supporting a serious-event flag.
